跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 64,698 条关于
“MEK1/2”
全部
64,698
临床试验
42,118
药物
7,318
机构
1,387
资讯
13,875
9个月前
Recursion's REC-4881 Shows Durable Polyp Reduction in Familial Adenomatous Polyposis Phase 2 Trial
9个月前
Recursion to Present Updated Clinical Data from Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis
去年
Pasithea's PAS-004 Outperforms FDA-Approved MEK Inhibitor in Preclinical IBD Study
10个月前
Long-Term Mirdametinib Data Shows Improved Response Rates and Deeper Tumor Shrinkage in NF1-Associated Plexiform Neurofibromas
8个月前
BEAVER Trial Demonstrates Efficacy of Binimetinib-Encorafenib Combination in Advanced Non-V600E BRAF-Mutated Tumors
2个月前
Macrophage Metabolic Reprogramming Emerges as a Key Driver of Chronic Transplant Rejection and a New Therapeutic Target
去年
Verastem Oncology Refinances Debt and Advances Avutometinib/Defactinib Combination
去年
Verastem Oncology's RAMP 203 Trial Shows Encouraging Initial Data for Triplet Combination in Advanced KRAS G12C Mutant NSCLC
去年
Mirdametinib Demonstrates Significant Tumor Reduction and Improved Quality of Life in NF1-Associated Plexiform Neurofibroma
上个月
Recursion Pharmaceuticals Advances First AI-Discovered Neuroscience Target with Genentech, Lowers Cash Burn Guidance
第 1 页,共 1388 页
上一页
下一页